Ocular melanoma

Archives of Pathology and Laboratory Medicine

Volumn 134, Issue 12, 2010, Pages 1778-1784

  Laver, Nora V ^a   McLaughlin, Margaret E ^a   Duker, Jay S ^a  

^a NEW ENGLAND EYE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CHROMOSOME ABERRATION; FEMALE; GENETICS; HUMAN; MELANOMA; METASTASIS; NEEDLE BIOPSY; PATHOLOGY; PROGNOSIS; UVEA TUMOR;

AGED; BIOPSY, FINE-NEEDLE; CHROMOSOME ABERRATIONS; FEMALE; HUMANS; MELANOMA; NEOPLASM METASTASIS; PROGNOSIS; UVEAL NEOPLASMS;

EID: 78650477168     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Singh AD, Topham A. Incidence of uveal melanomas in the United States: 1973-1997. Ophthalmology. 2003;110(5):956-961.
2. Bergman L, Seregard S, Nilsson B, et al. Uveal melanoma survival in Sweden from 1960 to 1998. Invest Ophthalmol Vis Sci. 2003;44(8):3282-3287.
3. Seddon JM, Young TA. Epidemiology of uveal melanoma. In: Ryan SJ, Hinton DR, Schachat AP, Wilkinson CP, eds. Retina. 4th ed. St Louis, MO: Elsevier Mosby; 2006:692-697.
4. Shields CL, Shields JA, Materin M, et al. Iris melanoma: risk factors for metastasis in 169 consecutive patients. Ophthalmology. 2001;108(1):172-178.
5. Singh AD, Shields CL, Shields JA, et al. Bilateral uveal melanoma: bad luck or bad genes? Opthalmology. 1996;103(2):256-262.
6. Mooy CM, De Jong PT. Prognostic parameters in uveal melanoma: a review. Surv Ophthalmol. 1996;41(3):215-228.
7. Johnson MW, Skuta GL, Kincaid MC, Nelson CC, Wolter JR. Malignant melanoma of the iris in xeroderma pigmentosum. Arch Ophthalmol. 1989;107(3):402-407.
8. Singh AD, De Potter P, Fijal BA, et al. Lifetime prevalence of uveal melanoma in white patients with oculo (dermal) melanocytosis. Ophthalmology. 1998;105(1):195-198.
9. Shields CL, Shields JA, Eagle RC Jr, et al. Uveal melanoma and pregnancy: a report of 16 cases. Ophthalmology. 1991:98 (11):1667-1673.
10. Diener-West M, Earle JD, Fine SL, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings-COMS report no. 18. Arch Ophthalmol. 2001;119(7):969-982.
11. Seddon JM, Albert DM, Lavin PT, Robinson N. A prognostic factor study of disease-free interval and survival following enucleation for uveal melanoma. Arch Ophthalmol. 1983;101(12):1894-1899.
12. Kath R, Hayungs J, Bornfeld N, et al. Prognosis and treatment of disseminated uveal melanoma. Cancer. 1993;72(7):2219-2223.
13. Seddon JM, Moy CS. Choroidal melanoma: prognosis. In: Ryan SJ, ed. Retina. 3rd ed. St Louis, MO: The CV Mosby Co; 2001:687-697.
14. Shields JA, Shields CL. Prognostic factors for uveal melanoma. In: Gospodarovicz M, O'Sullivan B, Sobin LH, eds. Prognostic Factors in Cancer. 3rd ed. Hoboken, NJ: Wiley-Liss; 2006:269-272.
15. McLean IW. Uveal nevi and malignant melanomas. In: Spencer WH, ed. Ophthalmic Pathology: An Atlas and Textbook. Philadelphia, PA: WB Saunders; 1996:2121-2217.
16. Shields JA, ed. Update on malignant ocular tumors. Int Ophthalmol Clin. 1993;33(3):129-135.
17. Shields JA, Shields CL. Posterior uveal melanoma: clinical and pathologic features. In: Shield JA, Shields CL, eds. Intraocular Tumors: A Text and Atlas. Philadelphia, PA: WB Sauders; 1992:117-136.
18. Shields JA, Shields CL. Posterior uveal melanoma: clinical features. In: Shields JA, Shields CL, eds. Intraocular Tumors: An Atlas and Textbook. 2nd ed. Philadelphia, PA: Wolkers Kluber/Lippincott Williams & Wilkins; 2008:86-115.
19. Shields CL, Furuta M, Thangappan A, et al. Metastasis of uveal melanoma millimeter-by-milimiter in 8033 consecutive eyes. Arch Ophthalmol. 2009;127(8):989-998.
20. Shields CL, Shields JA, Kiratli H, et al. Risk factors for growth and metastasis of small choroidal melanocytic lesions. Ophthalmology. 1995;102(9):1351-1361.
21. Diener-West M, Hawkins B, Markowitz JA, Shachat AP. A review of mortality from choroidal melanoma: a meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988. Arch Ophthalmol. 1992;110(2):245-250.
22. Callender GR. Malignant melanocytic tumors of the eye: a study of histologic types in 111 cases. Trans Am Acad Opththalmol Otolaryngol. 1931;36:131-142.
23. McLean IW, Foster WD, Zimmerman LE, Gamel JW. Modifications of Callender's classification of uveal melanoma at the Armed Forces Institute of Pathology. Am J Ophthalmol. 1983;96(4):502-509.
24. McLean IW, Zimmerman LE, Evans RM. Reappraisal of Callender's spindle A type of malignant melanoma of choroid and ciliary body. Am J Ophthalmol. 1978;86(4):557-564.
25. Folberg R, Mehaffey M, Gardner LM, et al. The microcirculation of choroidal and ciliary body melanomas. Eye. 1997;11(pt 2):227-238.
26. Eagle RC Jr. Intraocular tumors in adults. In: Eagle RC Jr, ed. Eye Pathology: An Atlas and Basic Text. Philadelphia, PA: WB Saunders; 1999:170-198.
27. Durie FH, Campbell AM, Lee WR, Damato BE. Analysis of lymphocytic infiltration in uveal melanoma. Invest Ophthalmol Vis Sci. 1990;31(10):2106- 2110.
28. Makitie T, Summanen P, Tarkkanen A, et al. Microvascular loops and networks as prognostic indicators in choroidal and ciliary body melanomas. J Natl Cancer Inst. 1999;91(4):359-367.
29. Rao RA, Stoleru MA, Price LL, McLean IW, Laver NV. Prognostic indicators of mortality in uveal malignant melanomas [abstract]. Invest Ophthalmol Vis Sci. 2005;46:3392.
30. Jager MJ, Hurks HM, Leviskaya J, Kiessling R. HLA expression in uveal melanoma: there is no rule without some exception. Hum Immunol. 2002;63(6):444-451.
31. Mäkitie T, Summanen P, Tarkkanen A, Kivelä T. Tumor-infiltrating macrophages (CD68 (+) cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2001;42(7):1414-1421.
32. Gamel JW, McLean IW, Greemberg RA, et al. Computerized histologic assessment of malignant potential: a method for determining the prognosis of uveal melanomas. Hum Pathol. 1982;13(10):893-897.
33. Gamel JW, McLean IW, Greenberg RA, et al. Objective assessment of the malignant potential of intraocular melanomas with standard microslides stained with hematoxylin-eosin. Hum Pathol. 1985;16(7):689-692.
34. Huntington A, Haugan P, Gamel J, McLean I. A simple cytological method for predicting the malignant potential of intraocular melanoma. Pathol Res Pract. 1989;185(5):631-634.
35. Gamel JW, McLean IW, McCurdy JB. Biologic distinctions between cure and time to death in 2892 patients with intraocular melanoma. Cancer. 1993;71(7):2299-2305.
36. Prescher G, Bornfeld N, Hirche H, et al. Prognostic implications of monosomy 3 in uveal melanoma. Lancet. 1996;347(9010):1222-1225.
37. Maat W, Jordanova ES, van Zelderen-Bhola SL, et al. The heterogeneous distribution of monosomy 3 in uveal melanomas: implications for prognostication based on fine-needle aspiration biopsies. Arch Path Lab Med. 2007;131(1):91-96.
38. Wiltshire RN, Elner VM, Dennis T, et al. Cytogenetic analysis of posterior uveal melanoma. Cancer Genet Cytogenet. 1993;66(1):47-53.
39. Schoenfield L, Pettay J, Tubbs RR, et al. Variation of monosomy 3 status within uveal melanoma. Arch Path Lab Med. 2009;133(8):1219-1222.
40. Damato B, Duke C, Coupland S, et al. Cytogenetics of uveal melanoma: a 7-year clinical experience. Ophthalmology. 2007;114(10):1925-1931.
41. Sisley K, Rennie IG, Parsons MA, et al. Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis. Genes Chromosomes Cancer. 1997;19(1):22-28.
42. Singh AD, Tubbs R, Biscotti C, et al. Chromosomal 3 and 8 status within hepatic metastasis of uveal melanoma. Arch Pathol Lab Med. 2009;133(8):1223- 1227.
43. Tschentscher F, Hüsing J, Hölter T, et al. Tumor classification based on gene expression profiling shows that uveal melanoma with and without monosomy 3 represent two distinct entities. Cancer Res. 2003;63(10):2578-2584.
44. Onken M, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res. 2004;64(20):7205-7209.
45. Bastian, BC, Le Boit PE, Hamm H, et al. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res. 1998;58(10):2170-2175.
46. Onken MD, Worley LA, Long MD, et al. Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci. 2008;49(12):5230-5234.
47. de Waard-Siebinga I, Hilders CG, Hansen BE, et al. HLA expression and tumor-infiltrating immune cells in uveal melanoma. Graefes Arch Clin Exp Ophthalmol. 1996;234(1):34-42.
48. Maat W, Ly LV, Jordanova E, et al. Monosomy of chromosome 3 and an inflammatory phenotype occur together in uveal melanoma. Inv Ophthalmol Vis Sci. 2008;49(2):505-510.
49. Toivonen P, Mäkitie T, Kujala E, Kivelä T. Microcirculation and tumorinfiltrating macrophages in choroidal and ciliary body melanoma and corresponding metastases. Invest Ophthalmol Vis Sci. 2004;45(1):1-6.
50. Figuereido A, Caissie LA, Callejo SA, et al. Cyclooxygenase-2 expression in uveal melanoma: novel classification of mixed-cell-type tumours. Can J Ophthalmol. 2003;38(5):352-356.
51. Shields CL, Cater JC, Shields JA, et al. Combination of clinical factors predictive of growth of small choroidal melanocytic tumors. Arch Ophthalmol. 2000;118(3):360-364.
52. Shields JA. Management of posterior uveal melanoma: past, present, future [editorial]. Retina. 2002;22(2):139-142.
53. Shields CL, Ganguly A, Materin M, et al. Chromosome 3 analysis of uveal melanoma using fine needle aspiration biopsy at the time of plaque radiotherapy in 140 consecutive cases: the Deborah Iverson, MD, lectureship. Arch Ophthalmol. 2007;125(8):1017-1024.
54. Shields CL, Furuta M, Berman EL, et al. Choroidal nevus transformation into melanoma: analysis of 2514 consecutive cases. Arch Ophthalmol. 2009;127(8):981-987.
55. The Collaborative Ocular Melanoma Study Group. COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, V: twelve-year mortality rate and prognostic factors-COMS report no. 28. Arch Ophthalmol. 2006;124(12):1684- 1693.
56. Triozzi PL, Eng C, Singh AD. Targeted therapy for uveal melanoma. Cancer Treat Rev. 2008;34(3):247-258.
57. Chang AE, Hynds Karnell L, Mench HR. The National Cancer Data Base report on cutaneous and non-cutaneous melanoma: a summary of 84, 836 cases from the last decade: the American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998;83(8):1664-1678.